human prepro-orexin promoter, jellyfish EGFP cDNA, Foot-and-mouth disease virus (FMDV derived) 2A peptide (F2A), Phage P1 Cre, mouse protamine intron and polyA Carrier x Noncarrier [C57BL/6JJcl] Carrier x Noncarrier [C57BL/6JJcl] true RBRC06806 <a href='https://brc.riken.jp/mus/pcr06806'>Genotyping protocol -PCR-</a> Prior to requesting the BIOLOGICAL RESOURCE, the RECIPIENT must obtain approval from the DEPOSITOR using the Approval Form. In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested. In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested. For profit use of the BIOLOGICAL RESSOURCE, the RECIPIENT must contact with the Intellectual Property Office, Nagoya University to obtain a prior written consent.RECIPIENT must contact the DEPOSITOR in the case of application for any patents or commercial use based on the results from the use of the BIOLOGICAL RESOURCE. Akihiro YAMANAKA オレキシン神経細胞特異的にCreとEGFPを発現するトランスジェニックマウス。Tgマウスは外見上特に異常は認められない。 Necessary documents for ordering:<ol><li>Approval form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_6.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_d.docx">English</A>)</li><li>Order form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_4.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_b.docx">English</A>)</li><li>Category I MTA: MTA for distribution with RIKEN BRC (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_5.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_c.docx">English</A>)</li><li>Acceptance of responsibility for living modified organism (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_7.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_g.docx">English</A>)</li><li>GFP Transfer License (<A HREF="https://web.brc.riken.jp/ja/method/link/gfp_conclude">Japanese</A> / <A HREF="https://web.brc.riken.jp/en/method/link/gfp_conclude">English</A>)<br>Please fill in the <A HREF="https://web.brc.riken.jp/en/wp-content/uploads/form/gfp_schedule_a.doc">Schedule A</A>, and submit two signed copies to us together with two signed copies of RIKEN BRC's MTA. Please also read <A HREF="https://web.brc.riken.jp/en/wp-content/uploads/form/gfp_schedule_b.doc"> Schedule B</A>. </li></ol> Orexin-EGFP-2A-Cre, B6-hOX-GFP/Cre Tg Orexin-EGFP-2A-Cre, B6-hOX-GFP/Cre Tg Orexin-EGFP-2A-Cre transgenic mice. Tg mice show no obvious abnormality. 名古屋大学環境医学研究所・山中章弘先生（2014）。C57BL/6J受精卵にTgインジェクションにより作出。 Fluorescent Proteins/lacZ System 条件を付加する。利用者は提供承諾書を用いて、事前に寄託者の承諾を得る。<br>研究成果の公表にあたって寄託者の指定する文献を引用する。<br>研究成果の公表にあたって謝辞の表明を必要とする。<br>営利目的利用の希望については、希望者は予め名大知財・技術移転グループに連絡し、承諾を得る。利用者が本件リソースを使用して得られた研究成果に基づき特許等の申請、及び事業活動を行う場合は、寄託者（名大知財・技術移転グループ）と別途協議を行う。 Cre/loxP system B（1〜3か月） Developed by Akihiro Yamanaka, Research Institute of Environmental Medicine Nagoya University in 2014. The transgene was injected into the pronuclei of C57BL/6J fertilized eggs. C57BL/6-Tg(hOX-EGFP,-cre)1Ahky C57BL/6-Tg(hOX-EGFP,-cre)1Ahky 山中　章弘 B (1-3 months)